Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Echocardiologists in Latin America Express Strong Interest in Ventripoint Whole Heart Analysis Products



Ventripoint Diagnostics Ltd.

Toronto, Ontario – TheNewswire – August 10, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) participated in the 11th Cardiovascular Imaging Conference (DIC) hosted by the Brazilian Society of Cardiology (SBC), 29-31 July 2022, in Sao Paulo, Brazil.

The SBC is Brazil’s top professional association with 13,500 members in 26 regional societies throughout the country. The DIC-SBC conference, co-sponsored by major ultrasound suppliers in the industry, attracted participants from leading cardiovascular centers, research universities, private clinics and government.

Ventripoint’s podium presentation, “A Rapid, Accurate and Reliable Technique to Analyze RV Function in Echocardiograms from Patients with Congenital Heart Defects (CHD)”, attracted 75 CHD clinicians. The presentation featured use of the company’s novel AI-based tool (VMS+3.0) to analyze standard 2D echocardiograms to generate 3D model and cardiac measurements with accuracy equivalent to MRI for the Right Ventricle (RV) and other chambers of the heart. Dr. Gregory Skinner (Glenfield Hospital, UK) presented two case studies to showcase the benefits of using VMS+3.0 for long-term follow-up of pediatric patients with the CHD, Tetralogy of Fallot, following pulmonary valve replacement. Dr. Skinner also commented he routinely takes the VMS+3.0 to the patients within the hospital and has successfully analyzed the heart of a 2.3-kilogram, premature baby in the neonatal ICU. The presentation drew strong expressions of interest from leading clinicians and institutions looking to adopt the system.

According to the DIC-SBC Conference Chairperson, Dr. Marly Uellendahl, “VMS+3.0 is an innovative technology that generates three-dimensional data from two-dimensional echocardiogram data and will have a major impact on clinical practice for sure, especially in evaluating the right ventricle."

"VMS+3.0 is the future of heart analytics and especially for CHD,” stated Dr. Adriana Mello, Vice-President of Congenital Echocardiology at DIC-SBC.

The need for VMS+3.0 units to diagnose CHD in South America is bigger than the United States. There are more children born with CHD in South America than North America (65,000 in North America and 71,000 in South America annually) and currently, there are 2.2 million adults with congenital heart disease in the United States, with more than 1.8 million in South America. (1)

The Brazil healthcare market includes private companies, HMOs and public institutions. The system features dedicated cardiovascular centres and teaching hospitals that are world class such as Instituto do Coração (InCor USP), Hospital do Coração (HCor) and Instituto Dante Pazzanese de Cardiologia (IDPC)in Sao Paulo.

The Company has engaged a representative in Brazil and he has initiated discussions with KOLs, distributors and regulatory consultants to establish a market entry plan and assess demand for VMS+ family of products in this rich region. The regulatory process in Brazil has recently been changed and it is estimated it will take 6 to 12 months to complete depending on the classification the VMS+.

  1. (1)John Jairo Araujo; “Adults with Congenital Heart Disease in the Americas - Where we are today and where we are heading: A General View of the Inter-American Adult Heart Disease Council (

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Copyright (c) 2022 TheNewswire - All rights reserved.